330
X. Yang et al.
14. International Conference on Chemicals Management Fourth Session (2015) Emerging policy
issues and other issues of concern (report by the secretariat). International Conference on
Chemicals Management Fourth Session, Geneva
15. Kavlock RJ, Daston GP, DeRosa C, Fenner-Crisp P, Gray LE, Kaattari S, Lucier G, Luster
M, Mac MJ, Maczka C, Miller R, Moore J, Rolland R, Scott G, Sheehan DM, Sinks T, Tilson
HA (1996) Research needs for the risk assessment of health and environmental effects of
endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Environ Health Perspect
104(S4):715–740
16. Schug TT, Johnson AF, Birnbaum LS, Colborn T, Guillette LJ Jr, Crews DP, Collins T, Soto
AM, Vom Saal FS, McLachlan JA, Sonnenschein C, Heindel JJ (2016) Minireview: endocrine
disruptors: past lessons and future directions. Mol Endocrinol 30(8):833–847
17. Dayan CM, Panicker V (2009) Novel insights into thyroid hormones from the study of common
genetic variation. Nat Rev Endocrinol 5(4):211–218
18. Murk ATJ, Rijntjes E, Blaauboer BJ, Clewell R, Crofton KM, Dingemans MM, Furlow JD,
Kavlock R, Köhrle J, Opitz R, Traas T, Visser TJ, Xia M, Gutleb AC (2013) Mechanism-based
testing strategy using in vitro approaches for identification of thyroid hormone disrupting
chemicals. Toxicol Vitro 27(4):1320–1346
19. Gilbert ME, Rovet J, Chen Z, Koibuchi N (2012) Developmental thyroid hormone disruption:
prevalence, environmental contaminants and neurodevelopmental consequences. Neurotoxicology 33(4):842–852
20. Li F, Yang XH, Chen JW, Lyakurwa F (2015) QSARs on the thyroid hormone effects of
polybrominated diphenyl ether (PBDE) derivatives (Chapter 17), In: Zeng EY (ed) Persistent organic pollutants (POPs): analytical techniques, environmental processes and biological
effects. Compr Anal Chem 67:547–586
21. Gohlke H, Klebe G (2002) Approaches to the description and prediction of the binding
affinity of small-molecule ligands to macromolecular receptors. Angew Chem Int Ed Engl
41(15):2644–2676
22. Rabinowitz JR, Little SB, Laws SC, Goldsmith MR (2009) Molecular modeling for screening
environmental chemicals for estrogenicity: use of the toxicant-target approach. Chem Res
Toxicol 22(9):1594–1602
23. Allen TE, Goodman JM, Gutsell S, Russell PJ (2014) Defining molecular initiating
events in the adverse outcome pathway framework for risk assessment. Chem Res Toxicol
27(12):2100–2112
24. Ankley GT, Edwards SW (2018) The adverse outcome pathway: a multifaceted framework
supporting 21st century toxicology. Curr Opin Toxicol 9:1–7
25. Willett CE, Bishop PL, Sullivan KM (2011) Application of an integrated testing strategy to
the U.S. EPA endocrine disruptor screening program. Toxicol Sci 123(1):15–25
26. Meerts IA, van Zanden JJ, Luijks EA, van Leeuwen-Bol I, Marsh G, Jakobsson E, Bergman
A, Brouwer A (2000) Potent competitive interactions of some brominated flame retardants
and related compounds with human transthyretin in vitro. Toxicol Sci 56(1):95–104
27. Weiss JM, Andersson PL, Lamoree MH, Leonards PE, van Leeuwen SP, Hamers T (2009)
Competitive binding of poly- and perfluorinated compounds to the thyroid hormone transport
protein transthyretin. Toxicol Sci 109(2):206–216
28. Ren XM, Qin WP, Cao LY, Zhang J, Yang Y, Wan B, Guo LH (2016) Binding interactions of
perfluoroalkyl substances with thyroid hormone transport proteins and potential toxicological
implications. Toxicology 366–367:32–42
29. Kavlock R, Dix D (2010) Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure,
hazard and risk. J Toxicol Environ Health B Crit Rev 13:197–217
30. Browne P, Casey WM, Dix DJ (2018) Use of high-throughput and computational approaches
for endocrine pathway screening. In: Garcia-Reyero N, Murphy C (eds) A systems biology
approach to advancing adverse outcome pathways for risk assessment. Springer, Cham
31. U.S. Environmental Protection Agency (2015) Use of high throughput assays and computational tools; endocrine disruptor screening program; notice of availability and opportunity for
comment federal register, pp 35350–35355
X. Yang et al.
14. International Conference on Chemicals Management Fourth Session (2015) Emerging policy
issues and other issues of concern (report by the secretariat). International Conference on
Chemicals Management Fourth Session, Geneva
15. Kavlock RJ, Daston GP, DeRosa C, Fenner-Crisp P, Gray LE, Kaattari S, Lucier G, Luster
M, Mac MJ, Maczka C, Miller R, Moore J, Rolland R, Scott G, Sheehan DM, Sinks T, Tilson
HA (1996) Research needs for the risk assessment of health and environmental effects of
endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Environ Health Perspect
104(S4):715–740
16. Schug TT, Johnson AF, Birnbaum LS, Colborn T, Guillette LJ Jr, Crews DP, Collins T, Soto
AM, Vom Saal FS, McLachlan JA, Sonnenschein C, Heindel JJ (2016) Minireview: endocrine
disruptors: past lessons and future directions. Mol Endocrinol 30(8):833–847
17. Dayan CM, Panicker V (2009) Novel insights into thyroid hormones from the study of common
genetic variation. Nat Rev Endocrinol 5(4):211–218
18. Murk ATJ, Rijntjes E, Blaauboer BJ, Clewell R, Crofton KM, Dingemans MM, Furlow JD,
Kavlock R, Köhrle J, Opitz R, Traas T, Visser TJ, Xia M, Gutleb AC (2013) Mechanism-based
testing strategy using in vitro approaches for identification of thyroid hormone disrupting
chemicals. Toxicol Vitro 27(4):1320–1346
19. Gilbert ME, Rovet J, Chen Z, Koibuchi N (2012) Developmental thyroid hormone disruption:
prevalence, environmental contaminants and neurodevelopmental consequences. Neurotoxicology 33(4):842–852
20. Li F, Yang XH, Chen JW, Lyakurwa F (2015) QSARs on the thyroid hormone effects of
polybrominated diphenyl ether (PBDE) derivatives (Chapter 17), In: Zeng EY (ed) Persistent organic pollutants (POPs): analytical techniques, environmental processes and biological
effects. Compr Anal Chem 67:547–586
21. Gohlke H, Klebe G (2002) Approaches to the description and prediction of the binding
affinity of small-molecule ligands to macromolecular receptors. Angew Chem Int Ed Engl
41(15):2644–2676
22. Rabinowitz JR, Little SB, Laws SC, Goldsmith MR (2009) Molecular modeling for screening
environmental chemicals for estrogenicity: use of the toxicant-target approach. Chem Res
Toxicol 22(9):1594–1602
23. Allen TE, Goodman JM, Gutsell S, Russell PJ (2014) Defining molecular initiating
events in the adverse outcome pathway framework for risk assessment. Chem Res Toxicol
27(12):2100–2112
24. Ankley GT, Edwards SW (2018) The adverse outcome pathway: a multifaceted framework
supporting 21st century toxicology. Curr Opin Toxicol 9:1–7
25. Willett CE, Bishop PL, Sullivan KM (2011) Application of an integrated testing strategy to
the U.S. EPA endocrine disruptor screening program. Toxicol Sci 123(1):15–25
26. Meerts IA, van Zanden JJ, Luijks EA, van Leeuwen-Bol I, Marsh G, Jakobsson E, Bergman
A, Brouwer A (2000) Potent competitive interactions of some brominated flame retardants
and related compounds with human transthyretin in vitro. Toxicol Sci 56(1):95–104
27. Weiss JM, Andersson PL, Lamoree MH, Leonards PE, van Leeuwen SP, Hamers T (2009)
Competitive binding of poly- and perfluorinated compounds to the thyroid hormone transport
protein transthyretin. Toxicol Sci 109(2):206–216
28. Ren XM, Qin WP, Cao LY, Zhang J, Yang Y, Wan B, Guo LH (2016) Binding interactions of
perfluoroalkyl substances with thyroid hormone transport proteins and potential toxicological
implications. Toxicology 366–367:32–42
29. Kavlock R, Dix D (2010) Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure,
hazard and risk. J Toxicol Environ Health B Crit Rev 13:197–217
30. Browne P, Casey WM, Dix DJ (2018) Use of high-throughput and computational approaches
for endocrine pathway screening. In: Garcia-Reyero N, Murphy C (eds) A systems biology
approach to advancing adverse outcome pathways for risk assessment. Springer, Cham
31. U.S. Environmental Protection Agency (2015) Use of high throughput assays and computational tools; endocrine disruptor screening program; notice of availability and opportunity for
comment federal register, pp 35350–35355